Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.63 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.63 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.63 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277287 | 0.95 | GNAI3 (0.63) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL4389217 | 0.95 | GNAI3 (0.57) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL6700154 | 0.91 | GNAI3 (0.63) | GNAI3GNAO1GNAI1 | |
| SCHEMBL4392316 | 0.91 | GNAI3 (0.52) | GNAI3GNAO1GNAI1DNM1 | |
| SCHEMBL9292459 | 0.88 | GNAI3 (0.67) | GNAI3GNAO1GNAI1DNM1 | |
| SCHEMBL4395108 | 0.88 | KEAP1 (0.54) | GNAI3GNAO1GNAI1DNM1MEN1 | |
| SCHEMBL1043043 | 0.87 | GNAI3 (0.70) | GNAI3GNAO1GNAI1 | |
| SCHEMBL4666999 | 0.87 | — | — | |
| SCHEMBL250855 | 0.87 | GNAI3 (0.70) | GNAI3GNAO1GNAI1 | |
| SCHEMBL35895 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | GNAI3 627/4885GNAO1 225/4885GNAI1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.